Adcetris® (brentuximab vedotin) plus standard of care chemotherapy demonstrates superior event-free survival (efs) vs. standard of care alone in children and young adults with previously untreated high-risk hodgkin lymphoma

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced results from a presentation by the children's oncology group (cog) of a phase 3 trial (ahod1331) evaluating adcetris® (brentuximab vedotin) in children and young adults with high-risk, previously untreated classical hodgkin lymphoma (chl). the trial showed adcetris in combination with standard of care dose-intensive chemotherapy ave-pc [adriamycin (doxorubicin), vincristine, etoposide, prednisone and cyclophosphamide] a
SGEN Ratings Summary
SGEN Quant Ranking